279 related articles for article (PubMed ID: 12739994)
1. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferons for the treatment of chronic hepatitis C infection.
Luxon BA; Grace M; Brassard D; Bordens R
Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
[TBL] [Abstract][Full Text] [Related]
3. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.
Hadziyannis SJ; Papatheodoridis GV
Expert Opin Pharmacother; 2003 Apr; 4(4):541-51. PubMed ID: 12667117
[TBL] [Abstract][Full Text] [Related]
5. Pegylated IFNs for chronic hepatitis C: an update.
Grace MJ; Cutler DL; Bordens RW
Expert Opin Drug Deliv; 2005 Mar; 2(2):219-26. PubMed ID: 16296749
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
[No Abstract] [Full Text] [Related]
8. Peginterferon-alpha(2b) and ribavirin.
Ahn J; Flamm S
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):17-25. PubMed ID: 15482168
[TBL] [Abstract][Full Text] [Related]
9. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
Annemans L; Warie H; Nechelput M; Peraux B
Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
[TBL] [Abstract][Full Text] [Related]
10. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Wang YS; Youngster S; Grace M; Bausch J; Bordens R; Wyss DF
Adv Drug Deliv Rev; 2002 Jun; 54(4):547-70. PubMed ID: 12052714
[TBL] [Abstract][Full Text] [Related]
11. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
12. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
14. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C.
Sebastiani G; Ferrari A; Boccato S; Pistis R; Alberti A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1077-82. PubMed ID: 17877515
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
17. Combined antiviral options for the treatment of chronic hepatitis C.
Medina J; García-Buey L; Moreno-Monteagudo JA; Trapero-Marugán M; Moreno-Otero R
Antiviral Res; 2003 Oct; 60(2):135-43. PubMed ID: 14638410
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon.
Adinolfi LE; Durante-Mangoni E; Salzillo M; Marrone A; Tripodi MF; Restivo L; Merola A; Zampino R; Ruggiero G
Intern Emerg Med; 2009 Dec; 4(6):485-90. PubMed ID: 19649689
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.
Kamal SM; Fehr J; Roesler B; Peters T; Rasenack JW
Gastroenterology; 2002 Oct; 123(4):1070-83. PubMed ID: 12360469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]